Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
LAVAL, Québec, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today provided a business update and announced its operating and financial results for the first quarter of fiscal 2022 ended June 30, 2021.
- LAVAL, Qubec, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST) today provided a business update and announced its operating and financial results for the first quarter of fiscal 2022 ended June 30, 2021.
- Moreover, Orphan Drug Designation from the FDA should provide seven years of marketing exclusivity in the U.S. post-launch.
- As a result, Acasti has received strong interest and continues to evaluate a variety of strategic options for CaPre.
- Management hosted a business update conference call held on August 4, 2021 at 1:00 p.m. Eastern Time.